The past few decades have seen a significant advance in deciphering the pathophysiology of inflammatory bowel disease. Surprisingly, this abundance of treatment options does not yield the expected long-term response rates to increase drug design. Additionally, the increase in treatability has triggered an increase in research into biomarkers that may help designate therapy for patients most likely to respond in the drug design process. Fortunately in the process of drug research, important steps have been taken in the Drug development area leading to the discovery of several interesting biomarkers that are still being validated. However, the pace of progress in the field, the mismatch between short-term endpoints in studies of drug design exploring biomarkers, the ambition of the disease community to change disease course, and the inability to have certainty about the validity of detected biomarkers underlines the need for critical evaluation to drug design and drug development. conduct drug Discovery research in this area. We have highlighted areas for improvement in drug discovery studies that will help optimize the use of available therapies and break the current treatment ceiling and drug design and drug development. The discovery of biomarkers for predicting treatment response in IBD is an area of ??prime importance, given the urgent need to break the current treatment ceiling. Still, understanding the interactions between drugs and the most complex of systems - intact beings - is the ultimate goal to make proper drug discovery and drug design.